Eyebright Medical(SH:688050)2021-04-19 16:00Financial Performance - Net profit attributable to shareholders was ¥36,007,232.48, representing a significant increase of 954.25% year-on-year[4]. - Operating revenue for the period was ¥84,409,414.34, marking a substantial growth of 222.01% compared to the same period last year[4]. - Basic earnings per share increased to ¥0.34, up 750.00% from ¥0.04 in the same period last year[4]. - The company reported non-recurring gains of ¥4,397,254.24 during the period[6]. - Operating profit for Q1 2021 was ¥40,093,593.73, up from ¥2,737,691.47 in Q1 2020, reflecting a substantial growth[22]. - The net profit for Q1 2021 was CNY 36,865,194.87, compared to CNY 6,183,269.27 in Q1 2020, indicating an increase of about 496%[24]. - The total profit for Q1 2021 was CNY 41,151,194.02, compared to CNY 6,677,512.46 in Q1 2020, which is an increase of about 516%[24]. Cash Flow - The net cash flow from operating activities was ¥30,512,472.57, a recovery from a negative cash flow of ¥6,460,002.39 in the previous year[4]. - The company's cash flow from operating activities was CNY 91,571,952.81 in Q1 2021, a significant rise from CNY 28,488,870.91 in Q1 2020, representing an increase of about 221%[26]. - Net cash flow from operating activities was 30,512,472.57 RMB, compared to a negative cash flow of -6,460,002.39 RMB in the same period last year, indicating a significant improvement[27]. - Total cash inflow from investment activities amounted to 505,210,000.00 RMB, while cash outflow was 778,447,570.94 RMB, resulting in a net cash flow from investment activities of -273,237,570.94 RMB[27]. - Cash flow from financing activities showed a net inflow of 4,900,000.00 RMB, contrasting with a net outflow of -3,531,973.00 RMB in the previous year[28]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,654,513,680.22, an increase of 0.98% compared to the end of the previous year[4]. - The company's total liabilities decreased by 32.34% in employee compensation, attributed to the distribution of bonuses from the previous year[12]. - The company's total assets as of March 31, 2021, were ¥1,654,513,680.22, compared to ¥1,638,526,272.37 at the end of 2020, indicating a slight increase of approximately 1.0%[18]. - Total liabilities decreased to ¥65,848,061.42 from ¥90,894,611.56, showing a reduction of about 27.5%[19]. - The company's total liabilities reached ¥90.89 billion, a decrease of ¥2.77 million from ¥93.67 billion[33]. Research and Development - The proportion of R&D investment to operating revenue decreased to 16.30%, down 8.23 percentage points from the previous year[4]. - R&D investment in Q1 2021 was RMB 13.75 million, an increase of 113.93% year-over-year, reflecting the company's commitment to innovation[11]. - Research and development expenses for Q1 2021 were ¥10,846,222.20, compared to ¥5,192,656.61 in Q1 2020, reflecting a 108.5% increase[22]. - The company plans to continue expanding its R&D projects and maintain high investment levels in innovation[11]. Shareholder Information - The total number of shareholders at the end of the reporting period was 11,532[7]. - Major shareholder 解江冰 holds 12.93% of the shares, totaling 13,594,779 shares[7]. Market and Product Development - The company signed a framework agreement to acquire Jiangsu Tianyan Pharmaceutical Technology Co., Ltd., with three color soft hydrophilic contact lens products approved by the National Medical Products Administration[16]. - The company has ongoing development in new products and technologies, including the multifocal intraocular lens and hydrophilic contact lenses[16]. - The company is focusing on market expansion through strategic acquisitions and product innovation[16].